Loading…
The Paul-Ehrlich-Institute granted approval for Cohort 5.
Oncolytics Biotech, Inc. announced that Germany's Medical Regulatory Body, The Paul-Ehrlich-Institute (PEI), has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. This approval allows the company to proceed with its clinical trial as planned.
The GOBLET study is a significant part of Oncolytics Biotech's research efforts, focusing on the development of innovative cancer treatments. With the PEI's approval, the company can now expand its patient base in this critical study.
As of the latest data, Oncolytics Biotech has a free float of 104,562,000 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.